Barbara is an accomplished Senior Executive, Board Member and Consultant with more than 25 years of success across the pharmaceutical, biotech and medical device industries. Leveraging extensive experience in pharmaceutical quality assurance her broad areas of expertise include leadership, risk assessment, project management and brand security.
Throughout her executive career, Barbara has held leadership positions at Barbara Falco Pharma Consult, LLC; Abbott Laboratories (formerly Kos Pharmaceuticals), and Johnson Matthey Pharmaceutical Materials. In her current role as a President and Owner of Barbara Falco Pharma Consult, she has been responsible for business development, creating quality management systems, strategic planning, regulatory strategy and remediation, and managing supplier company relationships. In her role as Executive Director of Quality Assurance at Kos Pharmaceuticals, she was responsible for developing company quality management systems, managing the supplier quality program and interfacing with global regulators to maintain regulatory compliance. At Abbott laboratories she was a key member of the transition team to transfer Kos products to Abbott facilities globally.
Barbara also has extensive experience managing and auditing suppliers as well as a background working in quality assurance and control in the API industry.
She spent over 10 years on the board of directors of the International Pharmaceutical Aerosol Consortium (IPAC-RS) where she served as the chair of the supplier quality working group which developed and published (2006 & 2011) guidelines for orally inhaled and nasal drug product component supplier quality.
Barbara continues to serve as a science advisor for IPAC-RS.